Thursday, 26 Apr 2018

You are here

Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery

JAMA reports the results of a 5 year Finnish study comparing the results of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass and shows that gastric bypass yielded greater weight loss at 5 years, the difference was not statistically significant, in patients with morbid obesity. 

The Sleeve vs Bypass (SLEEVEPASS) study included 240 adults with morbid obesity received open-label randomized intervention iwth either sleeve gastrectomy or gastric bypass with a 5-year follow-up period. The primary end point was weight loss evaluated by percentage excess weight loss. The pPrespecified equivalence margins were −9% to +9% excess weight loss.

The patients had a mean baseline BMI of 45.9, and 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension.  The results are shown in the table below:

 SleeveBypass
% Wt. Loss49%57%
DM remission37%45%
D/C Statins47%60%
D/C BP meds29%51%
Morbidity rate19%26%

 

 

 

 

 

 

 

 

While gastric bypass results were generally superior to gastric sleeve results, these were not significantly different. 

These results are similar to that seen in the STAMPEDE study showing similar (nonsignificant) but better results for bypass compared to gastric sleeve in the control of type II diabetes. (citation source: https://buff.ly/2rdYC3M

The five-year follow-up of this original study showed that:

  • 88% of gastric bypass and sleeve gastrectomy patients maintained healthy blood glucose levels without needinginsulin.
  • 29% of gastric bypass patients and 23% of sleeve gastrectomy patients achieved normal blood glucose levels
  • Weight loss was significantly greater with gastric bypass and sleeve gastrectomy compared than with medications 

The effects of both surgical procedures to normalize glucose levels did, however, diminish over time, and some late complications were noted with surgery.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Advisors Weigh COX-2 Inhibitor Safety

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?

Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.

Medicare Drug Prices Jump Ten Times the Inflation Rate

CNN reports that a new congressional analysis of Medicare drug pricing shows the prices of the 20 most commonly prescribed brand-name drugs have risen nearly 10 times the annual rate of inflation in the past five years.

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice.